Sequential treatment from bisphosphonate to denosumab improves lumbar spine bone mineral density in postmenopausal osteoporosis patients: A meta-analysis of randomized controlled trials

Xu Jiang,Siyi Hou,Xiaolei Deng,Liyou Hu,Jian Wang,Decai Hou

DOI: https://doi.org/10.1097/md.0000000000040594

IF: 1.6

2024-11-24

Medicine

Abstract:Osteoporosis is an insidious disease characterized by low bone mass and microarchitectural damage, [ 1 ] and postmenopausal women are a major risk group, with approximately 62% of postmenopausal women suffering from osteoporosis. [ 2 ] Fragility fractures due to osteoporosis have become a major public health threat owing to their significant morbidity, mortality, and healthcare burden. [ 3 ] Vertebral fractures are the most common type of fragility fractures. However, given that back pain, height shortening, and other symptoms can be dismissed as aging-related symptoms, the symptoms of vertebral fractures are often ignored. Furthermore, its low diagnosis and treatment rate greatly reduces the quality of life of patients and increases the risk of death. [ 4 ] Therefore, the prevention and control of osteoporosis in postmenopausal women are particularly important. The guidelines state that bone loss can be prevented through adequate calcium and vitamin D3 intake, smoking and alcohol cessation, and exercise therapy and recommend that medication should be administered for patients with reduced bone mass or low bone mass and a history of fragility fractures of the hip or spine. [ 5 ] Some scholars have suggested that menopause-related problems such as osteoporosis can be mitigated by delaying or prolonging the childbearing age of women. [ 6–8 ]

medicine, general & internal